线粒体靶向抗氧化剂MitoQ的抗肿瘤效应

摘要

采用噻唑蓝(MTT)法检测不同浓度 MitoQ 对肝癌 HepG2 细胞的毒性;凋亡诱导实验研究不同浓度MitoQ对HepG2细胞凋亡率的影响;裸鼠移植瘤模型研究MitoQ对肝癌HepG2荷瘤小鼠的抑瘤作用.结果表明,MitoQ对肝癌HepG2细胞的抑制作用随着浓度而增加;给药组凋亡率显著高于对照组(p<0.01);MitoQ在1、5、10 mg/kg剂量给药10 d后对小鼠的肿瘤生长均有抑制作用,与对照组相比,10 mg/kg剂量组肿瘤体积(p<0.01)和肿瘤质量(p<0.05)均有显著性差异.结果提示,MitoQ在体内体外均具有抑制肝癌HepG2细胞生长的作用.%MTT was used to detect the cell toxicity of different concentrations of MitoQ on liver cancer HepG2 cells. Apoptosis-inducing assay was used to detect the apoptosis rate on liver cancer HepG2 cells after the treatment with varying MitoQ concentrations. Xenograft tumor model assay was used to investigate the anti-tumor effects of MitoQ on HepG2 hepatocarcinoma-bearing mice. The results showed that the inhibitory effects of MitoQ on HepG2 cells increased with MitoQ concentration, and compared with control group, the administration group apoptosis rate was significantly higher (p<0.01). In nude mice xenograft tumor model assay, the tumor growth was all inhibited after the treatment with 1 mg/kg, 5 mg/kg, and 10 mg/kg MitoQ concentration after 10 d. When the mice were treated with 10 mg/kg MitoQ, tumor volume (p<0.01) and tumor mass (p<0.05) were significantly different from those of the blank group (p<0.01). The results indicate that MitoQ has antitumor effectin vivo andin vitro.